Literature DB >> 20692211

High-dose rate brachytherapy alone in postoperative soft tissue sarcomas with close or positive margins.

Jun Itami1, Minako Sumi, Yasuo Beppu, Hirokazu Chuman, Akira Kawai, Naoya Murakami, Madoka Morota, Hiroshi Mayahara, Ryoichi Yoshimura, Yoshinori Ito, Yoshikazu Kagami.   

Abstract

PURPOSE: In the management of soft tissue sarcomas, perioperative radiation therapy has been used to reduce the risk of local recurrence after resection. However, a significance of postoperative high-dose rate brachytherapy (HDRBT) remains to be studied. Retrospective analysis was performed to elucidate the role of postoperative HDRBT. METHODS AND MATERIALS: Twenty-five patients with 26 soft tissue sarcoma lesions underwent postoperative HDRBT using (192)Ir remote afterloader without external beam radiation therapy. Ninety-two percent of the lesions were Grade 2 or 3 malignancies, and 50% were resected with positive surgical margins. The remaining 50% had very close margins. Fourteen lesions were treated for local recurrences after previous resections. Applicators of HDRBT were placed during the operation to include only the tumor bed excluding surgical scars. Applied dose was mainly 36Gy/6 fractions/3 d b.i.d.
RESULTS: Five-year local recurrence-free survival was 78.2% in all the 26 lesions. Recurrences were not seen within the treated volume of HDRBT. Two groups were defined according to the marginal status and number of previous operations. Group 1 was the lesions with a positive margin and foregoing resections. The remaining lesions were classified as Group 2. Five-year local recurrence-free survival was 43.8% and 93.3% in Group 1 and Group 2, respectively with a statistically significant difference (p=0.004).
CONCLUSIONS: Postoperative HDRBT was effective in controlling local lesions; but in Group 1 lesions, addition of a wide field external beam radiation therapy seems to be necessary to improve the local control rate.
Copyright © 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20692211     DOI: 10.1016/j.brachy.2009.07.012

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  8 in total

1.  Early complications of high-dose-rate brachytherapy in soft tissue sarcoma: a comparison with traditional external-beam radiotherapy.

Authors:  Cynthia L Emory; Corey O Montgomery; Benjamin K Potter; Martin E Keisch; Sheila A Conway
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

2.  Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?

Authors:  Jason Klein; Alex Ghasem; Samuel Huntley; Nathan Donaldson; Martin Keisch; Sheila Conway
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

3.  Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma.

Authors:  Arash O Naghavi; Ricardo J Gonzalez; Jacob G Scott; John E Mullinax; Yazan A Abuodeh; Youngchul Kim; Odion Binitie; Kamran A Ahmed; Marilyn M Bui; Amarjit S Saini; Jonathan S Zager; Matthew C Biagioli; Douglas Letson; Louis B Harrison; Daniel C Fernandez
Journal:  Brachytherapy       Date:  2016-05-12       Impact factor: 2.362

4.  Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature.

Authors:  Koichi Ogura; Yasuo Beppu; Hirokazu Chuman; Akihiko Yoshida; Noboru Yamamoto; Minako Sumi; Hirotaka Kawano; Akira Kawai
Journal:  Sarcoma       Date:  2012-05-15

Review 5.  Evidence and clinical outcomes of adult soft tissue sarcomas of the extremities treated with adjuvant high-dose-rate brachytherapy - a literature review.

Authors:  Antonio Cássio Assis Pellizzon
Journal:  J Contemp Brachytherapy       Date:  2014-10-06

6.  Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic.

Authors:  Pranshu Mohindra; Sushil Beriwal; Mitchell Kamrava
Journal:  Brachytherapy       Date:  2020-05-01       Impact factor: 2.362

7.  Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas.

Authors:  Annalisa Cortesi; Andrea Galuppi; Rezarta Frakulli; Alessandra Arcelli; Fabrizio Romani; Gian Carlo Mattiucci; Giuseppe Bianchi; Stefano Ferrari; Andrea Ferraro; Andrea Farioli; Marco Gambarotti; Alberto Righi; Gabriella Macchia; Francesco Deodato; Savino Cilla; Milly Buwenge; Vincenzo Valentini; Alessio Giuseppe Morganti; Davide Donati; Silvia Cammelli
Journal:  J Contemp Brachytherapy       Date:  2017-06-05

Review 8.  Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents.

Authors:  Cameron M Callaghan; M M Hasibuzzaman; Samuel N Rodman; Jessica E Goetz; Kranti A Mapuskar; Michael S Petronek; Emily J Steinbach; Benjamin J Miller; Casey F Pulliam; Mitchell C Coleman; Varun V Monga; Mohammed M Milhem; Douglas R Spitz; Bryan G Allen
Journal:  Cancers (Basel)       Date:  2020-08-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.